Merrill Lynch jumps to first from 7th last year in a smaller market; says its focus is larger deals and clients.
Unlike India, the US is a free-pricing market.
To ensure transparency, the Third Eye Cinema Fund has roped in various agencies as auditors and advisors.
'Younger people are taking steps to prevent lifestyle diseases.'
'It is fascinating to partner with consumers on the journey of self-discovery and to help shape people's preferences -- that is what I find most exciting,' Nandini Piramal tells Abhineet Kumar and Aneesh Phadnis.
Indian firm to soon launch copycat of anti-breast-cancer drug.
A certain segment of the US pharma industry have become vocal about Indian policies on domestic content requirements and IPR.
Mathew Martoma, a former SAC Capital portfolio manager, faces 20 years in prison for securities fraud and five years for conspiracy
Ranbaxy did its maiden public issue in 1973.
The plan of UID/Aadhaar-based surveillance does not end with the collection of fingerprints and iris scan, it goes quite beyond it and poses a lethal threat to the idea of India, says Gopal Krishna.
'As I became a citizen of the United States of America, I knew I was supposed to be shedding my Indian citizenship, but at the end of the day, Mera dil hai Hindustani,' says Roopa Unnikrishnan, Rhodes Scholar, Commonwealth Gold Medalist and Arjuna Award winner.
Financial numbers can sometimes paint a rosy picture because of changes in the accounting policy or a one-time income.
'The government's proposal to store citizens' data including Aadhaar data under its Digital India initiative on cloud is violative of the citizens' human rights because the cloud is admittedly beyond India's jurisdiction.'
My goal is to implement the Sevak project all over India and make the villages true Gandhian villages -- self sustainable in every way, including health, says Dr Thakor Patel, head of the American Association of Physician of Indian Origin's Public Health Committee. Aziz Haniffa reports
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances